Gang Liu
Research Subjects
Gang Liu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Barbara Belli
Departments of Medicinal Chemistry, Cell Biology and Pharmacology, Technology Development, and DMPK and Toxicology, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States
2 shared publicationsDana Gitnick
Departments of Medicinal Chemistry, Cell Biology and Pharmacology, Technology Development, and DMPK and Toxicology, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States
2 shared publicationsDaniel K. Treiber
Departments of Medicinal Chemistry, Cell Biology and Pharmacology, Technology Development, and DMPK and Toxicology, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States
2 shared publicationsHelen Hua
Departments of Medicinal Chemistry, Cell Biology and Pharmacology, Technology Development, and DMPK and Toxicology, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States
2 shared publicationsJulia M. Ford Pulido
Departments of Medicinal Chemistry, Cell Biology and Pharmacology, Technology Development, and DMPK and Toxicology, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States
2 shared publicationsMichael F. Gardner
Departments of Medicinal Chemistry, Cell Biology and Pharmacology, Technology Development, and DMPK and Toxicology, 4215 Sorrento Valley Boulevard, San Diego, California 92121, United States
2 shared publications
Latest Publications
- 28 September 2012
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (12) , 997-1002
Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases
A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacokinetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the α-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.
- 28 September 2012
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (12) , 997-1002
Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases
A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacokinetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the α-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.
- 1 March 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (7) , 3250-3260
Discovery of Highly Potent and Selective Pan-Aurora Kinase Inhibitors with Enhanced in Vivo Antitumor Therapeutic Index
Serine/threonine protein kinases Aurora A, B, and C play essential roles in cell mitosis and cytokinesis. Currently a number of Aurora kinase inhibitors with different isoform selectivities are being evaluated in the clinic. Herein we report the discovery and characterization of 21c (AC014) and 21i (AC081), two structurally novel, potent, kinome-selective pan-Aurora inhibitors. In the human colon cancer cell line HCT-116, both compounds potently inhibit histone H3 phosphorylation and cell proliferation while inducing 8N polyploidy. Both compounds administered intravenously on intermittent schedules displayed potent and durable antitumor activity in a nude rat HCT-116 tumor xenograft model and exhibited good in vivo tolerability. Taken together, these data support further development of both 21c and 21i as potential therapeutic agents for the treatment of solid tumors and hematological malignancies.
- 1 March 2012
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (7) , 3250-3260
Discovery of Highly Potent and Selective Pan-Aurora Kinase Inhibitors with Enhanced in Vivo Antitumor Therapeutic Index
Serine/threonine protein kinases Aurora A, B, and C play essential roles in cell mitosis and cytokinesis. Currently a number of Aurora kinase inhibitors with different isoform selectivities are being evaluated in the clinic. Herein we report the discovery and characterization of 21c (AC014) and 21i (AC081), two structurally novel, potent, kinome-selective pan-Aurora inhibitors. In the human colon cancer cell line HCT-116, both compounds potently inhibit histone H3 phosphorylation and cell proliferation while inducing 8N polyploidy. Both compounds administered intravenously on intermittent schedules displayed potent and durable antitumor activity in a nude rat HCT-116 tumor xenograft model and exhibited good in vivo tolerability. Taken together, these data support further development of both 21c and 21i as potential therapeutic agents for the treatment of solid tumors and hematological malignancies.
- 1 March 2010
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 10 (4) , 419-33
Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Abstract: SCD1 is a novel target for the treatment of dyslipidemia, obesity, and other symptoms of metabolic syndrome. Extensive target validation has been obtained using SCD1-deficient mice, anti-sense oligonucleotide and RNA interference-mediated knockdown of SCD1, and has supported a controlling role for SCD1 in regulation of lipid biosynthesis and energy expenditure. In this review, the recent advances in small-molecule SCD1 inhibitors will be summarized. The pharmacological and adverse effects of SCD1 inhibitors in relevant rodent models will also be reviewed. The future prospect of SCD1 inhibition in the treatment of metabolic diseases will be discussed.
- 1 March 2010
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 10 (4) , 419-33
Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Abstract: SCD1 is a novel target for the treatment of dyslipidemia, obesity, and other symptoms of metabolic syndrome. Extensive target validation has been obtained using SCD1-deficient mice, anti-sense oligonucleotide and RNA interference-mediated knockdown of SCD1, and has supported a controlling role for SCD1 in regulation of lipid biosynthesis and energy expenditure. In this review, the recent advances in small-molecule SCD1 inhibitors will be summarized. The pharmacological and adverse effects of SCD1 inhibitors in relevant rodent models will also be reviewed. The future prospect of SCD1 inhibition in the treatment of metabolic diseases will be discussed.
- 19 August 2009
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 19 (9) , 1169-1191
Stearoyl-CoA desaturase inhibitors: update on patented compounds
(2009). Stearoyl-CoA desaturase inhibitors: update on patented compounds. Expert Opinion on Therapeutic Patents: Vol. 19, No. 9, pp. 1169-1191. doi: 10.1517/13543770903061311
- 19 August 2009
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 19 (9) , 1169-1191
Stearoyl-CoA desaturase inhibitors: update on patented compounds
(2009). Stearoyl-CoA desaturase inhibitors: update on patented compounds. Expert Opinion on Therapeutic Patents: Vol. 19, No. 9, pp. 1169-1191. doi: 10.1517/13543770903061311
- 8 April 2009
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 19 (6) , 885-891
Azacycloalkane derivatives as inhibitors of delta-9 stearoyl-coenzyme A desaturase
Extensive target validation has supported a controlling role for delta-9 stearoyl-CoA desaturase in the regulation of lipid biosynthesis and energy expenditure. A group of structurally related azacycloalkane derivatives are disclosed in the latest of a series of patent applications from Merck Frosst, some of which are claimed to inhibit delta-9 desaturase activity in HepG2 cells. These compounds have potential utility in the treatment of disorders associated with abnormal lipid synthesis and metabolism, in particular for obesity, diabetes, metabolic syndrome, insulin resistance, and hepatic steatosis, when administered either alone or in combination with other agents, for example, peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists.
- 8 April 2009
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 19 (6) , 885-891
Azacycloalkane derivatives as inhibitors of delta-9 stearoyl-coenzyme A desaturase
Extensive target validation has supported a controlling role for delta-9 stearoyl-CoA desaturase in the regulation of lipid biosynthesis and energy expenditure. A group of structurally related azacycloalkane derivatives are disclosed in the latest of a series of patent applications from Merck Frosst, some of which are claimed to inhibit delta-9 desaturase activity in HepG2 cells. These compounds have potential utility in the treatment of disorders associated with abnormal lipid synthesis and metabolism, in particular for obesity, diabetes, metabolic syndrome, insulin resistance, and hepatic steatosis, when administered either alone or in combination with other agents, for example, peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists.